Countries China
Shineco Launches Innovative Product to Transform Healthcare
Shineco, a provider of technologically advanced healthcare products and services, announced that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. a...
May 02, 2024 | News
Chipscreen's Chidamide Receives NMPA Approval for First-Line Treatment of DLBCL with MYC/BCL2 Expression
Shenzhen Chipscreen Biosciences announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetyla...
May 01, 2024 | News
Jacobio Pharma Reports Promising Phase II Results for Glecirasib in Lung Cancer at ASCO
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at th...
May 01, 2024 | News
WuXi AppTec Reports First Quarter 2024 Financial Results: Solid Performance with Continued Growth in R&D Services
First Quarter 2024 Financial Highlights: Revenue of RMB 7,982 million, with a slight decrease of 1.8% in non-COVID-19 commercial projects, underscoring ...
April 30, 2024 | Company results
Sino Biological Completes $48M Acquisition of Canadian Firm SignalChem Biotech
Sino Biological, Inc. , a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, specializing in biological research reagents...
April 29, 2024 | News
Dizal to Present New Data on Sunvozertinib for Lung Cancer at ASCO 2024
Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases...
April 25, 2024 | News
GenFleet Therapeutics Secures FDA Approval for Pioneering Phase III KRAS G12C Inhibitor Trial in Colorectal Cancer
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Adm...
April 22, 2024 | News
Teva Validates AJOVY® Efficacy and Safety in China Phase 3 Migraine Trial
AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significanc...
April 15, 2024 | News
TransThera Sciences Presents Breakthrough Research on Tinengotinib for Advanced Solid Tumors with FGFR1-3 Alterations at AACR 2024
TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster present...
April 15, 2024 | News
BioCity Biopharma's Cancer Therapy BC2027 Gets FDA Nod for Phase 1 Trials
BioCity Biopharma announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Pha...
April 10, 2024 | News
D3 Bio Secures $62M in Series A+ Financing for Cancer Drug Development
D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its cl...
April 09, 2024 | News
Transcenta and Agilent Collaborate on Companion Diagnostic for Advanced Gastric Cancer Trial
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...
April 09, 2024 | News
Dizal's Sunvozertinib Secures FDA Breakthrough Therapy Designation for First-Line EGFR Mutated NSCLC Treatment
Dizal announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the firs...
April 08, 2024 | News
Merck Expands M Lab™ Collaboration Center in Shanghai
Additional € 14 million investment provides new opportunities for local and regional clients Adds 2,000 square meters of new collaboration space, i...
April 05, 2024 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
